Trials / Unknown
UnknownNCT04512339
Dupilumab in Severe Chronic Hand Eczema
Dupilumab in Severe Chronic Hand Eczema With Inadequate Response or Intolerance to Alitretinoin
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- University Medical Center Groningen · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficacy of dupilumab in hand eczema patients with an inadequate response or intolerance to alitretinoin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dupilumab | Dupilumab injections (blinded labels) |
| DRUG | Placebo | Placebo injections (blinded labels), matching the dupilumab injections in quantity and appearance |
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2022-08-01
- Completion
- 2022-08-01
- First posted
- 2020-08-13
- Last updated
- 2022-08-23
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04512339. Inclusion in this directory is not an endorsement.